摘要
目的:检测乙酰肝素酶(heparanase Hpa)、尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator uPA)在正常子宫内膜、增生过长子宫内膜、不典型增生子宫内膜及子宫内膜腺癌中的表达及相关性。探讨Hpa、uPA表达与子宫内膜癌临床病理特征的关系。
方法:采用多克隆抗体及免疫组织化学S-P法,检测16例正常子宫内膜、18例增生过长子宫内膜、20例不典型增生子宫内膜及46例子宫内膜腺癌中Hpa、uPA的表达。同时分析二者表达与子宫内膜癌临床病理分期、癌灶肌层浸润深度、淋巴结转移和组织病理学分级的相关性。
结果:
1、Hpa在子宫内膜癌中阳性表达率为54%,明显高于正常子宫内膜、增生过长内膜以及不典型增生子宫内膜中的表达,差异有显著性(P＜0.005)。Hpa在子宫内膜癌中的阳性表达率随临床分期的增加而增加,Ⅲ期患者内膜癌组织中Hpa阳性率(89%)明显高于Ⅰ期(33%)、Ⅱ期(69%)患者,有显著性差异(P=0.008)。Hpa在肌层浸润＞1/2中阳性表达率为77%,明显高于无肌层浸润(25%)或浸润≤1/2组(38%)(P＜0.05)。Hpa与子宫内膜癌临床病理分期、肌层浸润深度、淋巴结转移密切相关(P＜0.05),与病理分级无明显相关性(P＞0.05)。
2.uPA在正常子宫内膜、增生过长子宫内膜以及不典型增生子宫内膜和子宫内膜癌中的阳性表达率分别为13%、11%、25%和57%,uPA在子宫内膜癌组织中的表达明显高于正常内膜,差异有统计学意义(P＜0.005)。uPA在内膜癌Ⅲ期患者的阳性表达率(89%)明显高于Ⅰ期(38%)、Ⅱ期(69%)患者,有显著性差异(P=0.016)。uPA在肌层浸润＞1/2中阳性表达率为77%,明显高于无肌层浸润(38%)或浸润≤1/2组(38%)(P＜0.05)。uPA与子宫内膜癌临床病理分期、肌层浸润深度、淋巴结转移密切相关(P＜0.05),亦与病理分级无明显相关性(P＞0.05)。
3、Hpa与uPA相关性分析显示,二者的表达无明显相关性(p＞0.05)。
结论:
1.Hpa和uPA在子宫内膜腺癌组织中的表达明显高于正常子宫内膜、增生过长子宫内膜以及不典型增生子宫内膜组织,可能与子宫内膜癌的发生有关。
2.Hpa和uPA在子宫内膜腺癌组织中的表达均与临床病理分期、肌层浸润深度和淋巴结转移密切相关,与病理分级无明显相关性,提示Hpa和uPA可能在癌的侵袭、转移中起作用,并提示二者可作为反映子宫内膜癌生物学行为的参考指标。
3.Hpa和uPA在子宫内膜腺癌组织中的表达均升高,但无明显相关性,二者在内膜癌中有无相互作用还有待于进一步的研究。
Objectives: To detect the expression of Hpa (heparananse) and uPA (urokinase-type plasminogen activator) in the normal endometrium, over-hyperplasia endometrium, atypical hyperplasia endometrium and endometrial adenocarcinoma. To explore the relation between the expression of Hpa and uPA in the clinical pathological characteristics of endometrial carcinoma.
Methods: The multiple clonal antibodies and the S-P immunohistochemical method were adopted to detect the expression of Hpa and uPA in 16 cases of the normal endometrium, 18 cases of the over-hyperplasia endometrium, 20 cases of atypical hyperplasia endometrium and 46 cases of endometrial adenocarcinoma. At the same time, the correlation between the expression of Hpa and uPA and the clinical pathological staging of endometrial carcinoma, the degree of depth of infiltration at muscular lever of carcinoma focus, the metastasis of lymph nodes and the pathological grading of tissues was analyzed.
Results:
1.The positive expression rate of Hpa in the endometrial carcinoma was 54%, which was obviously higher than that in the normal endometrium, over-hyperplasia endometrium and atypical hyperplasia endometrium, presenting a marked difference (P<0.005). The positive expression rate of Hpa in endometrial carcinoma increased with the increase of clinical staging. The positive rate of Hpa in stage-Ⅲendometrial carcinoma patients(89%) was obviously higher than stage-Ⅰ(33%) and stage-Ⅱ(69%) patients and the difference was notable (P=0.008). The positive expression rate of Hpa in the patients that muscular infiltration depth were over 1/2 was 77%, which was obviously higher than that at non-muscular infiltration (25%) or muscular infiltration depth was less than or equal to 1/2 (38%) (P<0.05). Hpa was closely related to the clinical pathological staging of endometrial carcinoma, the degree of depth of infiltration at muscular lever and the metastasis of lymph nodes (P<0.05) and not show close relation with the pathological grading (P>0.05).
2. The positive expression rate of uPA in the normal endometrium, over-hyperplasia endometrium and atypical hyperplasia endometrium and endometrial carcinoma was 13%, 11%, 25% and 57% respectively. The expression of uPA in the tissue of endometrial carcinoma was obviously higher than that in normal endomembrane and the difference bore significance in statistics (P<0.005). The positive rate of uPA in endometrial carcinoma of a stage-Ⅲpatient (89%) was obviously higher than a stage-Ⅰ(38%) patient and stage-Ⅱ(69%) patient and the difference was significant (P=0.016). The positive expression rate of uPA in the patients that muscular infiltration depth were over 1/2 was 77%, which was obviously higher than that at non-muscular lever (38%) and that was less than or equal to 1/2 (38%) (P<0.05). uPA was closely related to the clinical pathological staging of endometrial carcinoma, the degree of muscular infiltration depth and the metastasis of lymph nodes (P<0.05) and not show close relation with the pathological grading (P>0.05).
3.The analysis of correlation between Hpa and uPA expression indicated that there were no obvious relevance (P>0.05).
Conclusion:
1. The expression of Hpa and uPA in endometrial adenocarcinoma was obviously higher than that of the normal endometrium, over-hyperplasia endometrium and atypical hyperplasia endometrium. The result indicated the possibility of occurrence of endometrial carcinoma.
2. The expression of Hpa and uPA in endometrial adenocarcinoma was closely related to the clinical pathological staging, the depth of infiltration at muscular lever and the metastasis of lymph nodes and not show close relation with the pathological grading, which indicated the possible role Hpa and uPA played in the invasion and metastasis of a carcinoma and both of them may be used as reference index for biological behavior of endometrial carcinoma.
3. Both Hpa and uPA increased in the expression of tissues of endometrial adenocarcinoma, however, there existed no obvious correlation. Further researches were needed to determine whether there existed interaction between Hpa and uPA in endometrial carcinoma.
引文
[1]丰有吉,沈铿。妇产科学.北京:人民卫生出版社,2006:240-325
[2]Vlodavsky I,Goldshmidt O,Zcharia E,et al.Mammalian heparanase:involvement in cancer metastasis,angiogenesis and normal development.Cancer Biology,2002,12:121-129
[3]Mc Kenzie E,Tyson K,Stamps A,et al.Commun cloning and expression profiling of Hap2,a novel mammalian heparanase family member.Biochem Biophys Res Commun,2000,276(3):1170-1177
[4]Vlodavsky I,Friedmann Y,Molecular properties and involvement of heparanase in- cancer metastasis and angiogenesis.J Clin Invest,2001,108(3):341-347
[5]Vlodavsky I,Friedmann Y,Elkin M,et al.Mammalian heparanase:gene cloning,exptession and function in tumor progression and metastasis[J].Nat Med,1999,5(7):793-802
[6]Ikuta M,Podyma KA,Maruyama K,et al.Expression of heparanase in oral cancer cell lines and oral cancer tissues.Oral Oncol,2001,37(2):177-184
[7]Mikami S,Ohashi K,Usui Y,et al.Loss of syndecan-1 and increased expression of heparanse in invasion esophageal carcinomas.Jpn J Cancer Res,2001,92(10):1062-1073
[8]Sasaki M,Ito T,Kashima M,et al.Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanse mRNA on human lung cancer cells in vitro.Mediator Inflamm,2001,10(5):259-267
[9]Marchetti D,Li J,Shen R.hstrocytes contribute to the brainmetastatic specificity of melanoma cells by producing heparanase.Cancer Res,2000,60(17):4767-4770
[10]Marchetti D,Nicolson GL.Human melanoma cell invasion:selected neurotrophin enhancement of invasion and heparanase activity.J Investig Dermatol Symp Proc, 1997, 2(1): 99-105
[11]Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic cancer. Cancer Res, 2001, 61 (12): 4655-4659
[12]Walch ET , Matchetti D. Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin Exp Metasrasis, 1999, 17 (4): 307-314
[13]Gohji K, HiranoH, Okamoto M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer, 2001, 95 (5): 295-301
[14]Dano K, Andreason PA, Grondahl-Hansen K, et al. Plasminogen activators, tissue degradation and cancer[J].Adv Cancer Res, 1985, 44(2): 139-266
[15] Boss EA, Massugr LF, Thomas CM, et al.Clinical value of components of the plasminogen activation system in ovarian cyst fluid[J].Anticancer Res, 2002, 22 (1): 275-282
[16]Borgfeldt C, Hansson SR, Gustavsson B, et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-I) [J]. Int J Cancer, 2001, 92 (4): 497-502
[17]Usher PA, Thomsen OF, Iversen P, et al. Expression of urokinase plasminogen activator, its receptor and type-2 inhibitor in malignant and benign prostate tissue[J]. Int J Cancer, 2001, 92 (4): 497-502
[18]Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13: 781-792
[19] Eccles SA. Heparanase: breaking down barriers in tumors[J]. Nat Med, 1999, 5 (7): 735-736
[20]Finkel E.Potential target found for antimetastasis drugs.Science 1999, 285: 33-34
[21] Hulett MD, Freeman C, Hamdorf BJ, et al. Cloning of mammalian heparanase , an important enzyme in tumor invasion and metastasis[J].Nat Med,1999,5(7):803-809
[22]Fairbanks MB,Mildner AM,Leone JW,et al.Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer[J].J Biol Chem,1999,274(42):29587-29590
[23]Bame KJ.Heparanases:endoglycosidases that degrade heparan sulfate proteoglycans.Glycobiology 2001,11:91R-98R
[24]Eccles SA.Heparanase:breaking down barriers in tumors[J].Nat Med,1999,5(7):735-736
[25]Dempsey LA,Brunn GJ,Platt JL.Heparanase a potential regulator of cell-matrix interactions[J].Trends Biochem Sci,2000,26(8):349-351
[26]Vaday GG,Lider O,Extracellular matrix moietics,cytokines,and enzymes:dynamic effects on immune cell behavior and inflammation[J].J Leukocyte Biol,2000,67(2):149-159
[27]Vlodavsky I,Elkin M,Poppo O,et al.Mammalian heparanase asmediator of tumor metastasis and angiogenesis.Isr Med Assoc J,2000;2[Suppl]:37-45
[28]Wojtukiewicz M,Sierko E,Zacharski LR,et al.Occurrence of components of fibriolytic pathways in situ in laryngeal cancer[J].Semin Thromb Hemost,2003,29(3):317-320
[29]李节,邱平.尿激酶与肿瘤转移[J].国外医学分子生物分册,1994,16(1):26-28
[30]Watanabe M,Aoki Y,Kase H,et al.Heparanase expression and angiogenesis in endometrial cancer.Gynecol Obstet Invest,2003,56:77-82
[31]Goldshmidt O,Zcharia E,Cohen M,Aingorn H,Cohen I,et al.Heparanase mediates cell adhesion independendent of its enzymatic activity.Faseb J,2003,17:1015-1025
[32]Shinyo Y,Kodama J,Hongo A,et al.Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer[J].Ann Oncol,2003,14(10):1505-1510
[33]Boyd DD,Nakajima M.Involvement of heparanase in tumor metastases:a new target in cancer therapy? J Natl Cancer Inst,2004,96:1194-1195
[34]Daemi N,Thomasset N,Lissitzky JC,et al.Anti-beta4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP-2 expression.Int J Cancer,2000,85:850-856
[35]崔红梅,王海琳,别雅春,等.宫颈癌中HPA的表达与细胞增殖、血管生成和转移的关系.实用妇产科杂志,2006,22(3):154-157
[36]李丽,牛保华,王国平.宫颈上皮内瘤变、宫颈癌中乙酰肝素酶的表达及意义.山东医药,2007,47(18):9-10
[37]Edovitsly E,Elkin M,Zcharia E,et al.Heparanase gene silencing,tumor invasiveness,angiogenesis,and metastasis.Natl Cancer Inst,2004,96(16):1219-1230
[38]Taponeco F,Curcio C,Giuntini A,et al.Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1in endometrial hyperplasia and cancer[J].J Exp Clin Cancer Res,2001,20(2):239-246
[39]Van der Burg ME,Henzen-Logmans SC,Berns EM,et al.Expression of urokinase-type plasminogen activator(uPA) and its inhibitor PAI-1in begin,borderline,malignant primary and metastatic ovarian tumors Int[J].Cancer,1996,69(6):475-479
[40]Riethdorf L,Riethdorf S,Petersen S.et al.Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix.[J].Pathol,1999,189(2):245-250
[41]Memarzadeh S,Kozak KR,Chang L,et al.Urokinase plasminogen activator receptor:Prognostic biomarker for endometrial cancer[J].Proc Natl Acad Sci USA,2002,99(16):10647-52
[42]Gerstein ES,Gristsaenko EV,Shcherbakov ME,et al,Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia[J].Vopr Onkol,2003,49(6):725-9.Russian
[43]Iiotta LA,Stetler PS,Stetler-Stevenson WG.Cancer metastasis and angiogenesis:an imbalance of positive and negative and negulative regulation[J].Cell,1991,64(2):327-336
[44]Stahl A,Mueller BM.Binding of urokinase to its receptor promotes migration and invasion and invasion of human melanoma cells in vitro[J].Cancer Res,1994,54:3066-3071
[45]Tecimer C,Ooering DL,Goldsmith LJ,et al.Clinical relevance of urokinase-type plasminogen activator,its receptor,and its inhibitor type 1 in endometrial cancer[J].Gynecol Oncol,2001,80(1):48-55
[46]Flondon C,Nielsen O,Holund B,et al.Localization and significance of urokinase plasmincgen activator and receptor in placental tissue fron intrautenne,ectopic and molar pregnauceres[J].Placenta,1999,20(8):711-721
[47]Del Vecchio S,Stoppelli MP,Carriero MV,et al.Human urokonase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography:comparison with urokinase levels[J].Cancer Res,1993,53(13):3198-3206
[48]Duggan C,Maguire T,Mcdermott E,et al.Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer[J].Int J Cancer,1995,61(3):597-600
[49]Hasui Y,Marutsuka K,Nishi S,et al.Zhe content of urokinase type plasminogen activator and tumor recurrence in superficial bladder cancer[J].J Urol,1994,151(1):16-20
[50]Saluda-Geogul A,Pytel J,Olborski B,et al.Atigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer[J].Z Naturforseh,2002,57:366-371
[51]杨仕明,汤旭东,陈婷,等.肝素酶:一种新的广谱的肿瘤转移相关抗原在中晚期肿瘤免疫治疗中的作用研究进展.世界华人消化杂志,2007,15(8):849-853
[1]Hulett MD,Freeman C,Hamdorf BJ,et al.Cloning of mammalian heparanase,an important enzyme in tumor invasion and metastasis[J].Nat Med,1999,5(7):803-809
[2]Vlodavsky I,Friedmann Y,Elkin M,et al.Mammalian heparanase:gene cloning,exptession and function in tumor progression and metastasis[J].Nat Med,1999,5(7):793-802
[3]MeKenzie E,Tyson K,Stamps A,et al.Cloning and expression profiling of Hpa2,a novel mammalian heparanase family member.Biochem Bidphy Res Commun,2000,276(3):1170-1177
[4]Fairbanks MB,Mildner AM,Leone JW,et al.Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer[J].J Biol Chem,1999,274(42):29587-29590
[5]Mc Kenzie E,Tyson K,Stamps A,et al.Commun cloning and expression profiling of Hap2,a novel mammalian heparanase family member.Biochem Biophys Res Commun,2000,276(3):1170-1177
[6]Vlodavsky I,Elkin M,Poppo O,et al.Mammalian heparanase asmediator of tumor metastasis and angiogenesis.Isr Med Assoc J,2000,2[Suppl]:37-45
[7]Vlodavsky I,Friedmann Y,Molecular properties and involvement of heparanase in- cancer metastasis and angiogenesis.J Clin Invest,2001,108(3):341-347
[8]崔红梅,王海琳,别雅春,等.宫颈癌中HPA的表达与细胞增殖、血管生成和转移的关系.实用妇产科杂志,2006,22(3):154-157
[9]李丽,牛保华,王国平.宫颈上皮内瘤变、宫颈癌中乙酰肝素酶的表达及意义.山东医药,2007,47(18):9-10
[10]Watanabe M,Aoki Y,Kase H,et al.Heparanase expression and angiogenesis in endometrial cancer.Gynecol Obstet Invest,2003,56: 77-82
[11]王淑,崔金全,郭社珂.乙酰肝素酶和碱性成纤维生长因子与子宫内膜癌的关系.医药论坛杂志,2005,26(23):14-16
[12]He X,Brenchley PE,Jayson GC,et al.Hypoxia increases heparanase dependent tumor cell invasion,which can be inhibited by antiheparanse antibodies.Cancer Res,2004,64(11):3928-3933
[13]韩静,杨鹰,阎萍等.乙酰肝素酶在卵巢癌组织中的表达及其临床意义.第三军医大学学报,2006,28(20):2054-2056
[14]Jianchi D,Xiulong X,Jikun S,et al.Heparanase-1 expression in endometrium duing menstrual cycle in healthy control women and in women with endome-triosis.Fertil Steril,2002,78(1):S88
[15]蔡净亭,张怡,李梦熊等.乙酰肝素酶mRNA在子宫内膜异位症和子宫腺肌病中表达的研究.现代妇产科进展,2006,15(2):100-102
[16]袁劲进,刘玉,丁彦青.乙酰肝素酶在妇产科疾病关系的研究进展.中国妇幼保健,2001,16(5):325-327
[17]余蓉,张怡,蔡净亭.乙酰肝素酶与绒毛膜癌侵袭能力的关系.中华妇产科杂志,2007,42(10):692-695
[18]Parish CR,Freemam C,Brown KJ,et al.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.Cancer Res,1999,59(14):3433-3441
[19]Miao HQ,Elkin M,Aingorn E,et al.Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.Int J Cancer,1999,83(3):424-431
[20]Edovitsky E,Elkin M,Zcharia E,et al.Heparanase gene silencing,tumor invasiveness,angiogenesis,and metastasis[J].JNatl Cancer Inst,2004,96(16):1219-1230
[1]Liu S,Bugge TH,Leppla SH.Targeting of tumor by cell surface urokinase plasminogen activator-dependent anthrax[J].J Biol Chem,2001,276(21):17976-17984
[2]Wojtukiewicz M,Sierko E,Zacharski LR,et al.Occurrence of components of fibriolytic pathways in situ in laryngeal cancer[J].Semin Thromb Hemost,2003,29(3):317-320
[3]Podor IJ,Shaughnessy SG,Blackburn MN,et al.New insights int the size and stoichiometry of the plasminogen activator inhibitor type-1,vitronectin complex[J].J Biol Chem,2000,275(33):25402-25410
[4]李节,邱平.尿激酶与肿瘤转移[J].国外医学分子生物分册,1994,16(1):26-28
[5]Czekay RP,Aertgeerts K,Curriden SA,et al.Plasminogen activator inhibitor type-1 detaches cells from extracellular matrices by inactivating integrins[J].J Biol,2003,160(5):781-791
[6]Blouse GE,Perron MJ,Thompson JH,et al.Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins[J].Cell Biochemistry,2002,41(40):11997-12009
[7]ALLgayer H,Babic R,Gruelzner KU,et al.c-erB-2 is of independentprognostic cancer and is associated protease systems[J].J Clin Oncol,2000,18(11):2201-2209
[8]Van der Burg ME,Henzen-Logmans SC,Berns EM,et al.Expression of urokinase-type plasminogen activator(uPA) and its inhibitor PAI-1in begin,borderline,malignant primary and metastatic ovarian tumors Int[J].Cancer,1996,69(6):475-479
[9]Saluda-Geogul A,Pytel J,Olborski B,et al.Atigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer[J].Z Naturforseh,2002,57:366-371
[10]Del Vecchio S,Stoppelli MP,Carriero MV,et al.Human urokonase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography : compatison with urokinase levels[J].Cancer Res, 1993, 53 (13): 3198-3206
[11]Duggan C,Maguire T,Mcdermott E,et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer[J]. Int J Cancer, 1995, 61 (3): 597-600
[12]Taponeco F, Curcio C, Giuntini A, et al. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer[J]. J Exp Clin Cancer Res, 2001,20 (2): 239-246
[13] Tecimer C, Doering DL, Goldsmith LJ, et al. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer[J]. Gynecol Oncol, 2001, 80 (1): 48-55
[14]Riethdorf L, Riethdorf S, Petersen S. et al. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix.[J]. Pathol, 1999, 189 (2): 245-250
[15]Flondon C, Nielsen O, HolundB, et al. Localization and significance of urokinase plasmincgen activator and receptor in placental tissue fron intrautenne, ectopic and molar pregnauceres[J]. Placenta, 1999,20 (8): 711-721
[16]Jankun J, Skrzypczak Jankun E. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride[J]. Cancer Biochem Bilphys, 1999, 17 (1-2): 109-123
[17]HsuDW, EfirdJT, Hedley Whyte ET, et al. Prognostic role of urokinase type plasminogen activator in human gliomas[J]. Am J Pat Hol, 1995,147 (1): 114-123